Influence of p53 and caspase 3 activity on cell death and senescence in response to methotrexate in the breast tumor cell

被引:48
作者
Hattangadi, DK [1 ]
DeMasters, GA [1 ]
Walker, TD [1 ]
Jones, KR [1 ]
Di, X [1 ]
Newsham, IF [1 ]
Gewirtz, DA [1 ]
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA
关键词
breast tumor; apoptosis; senescence; methotrexate; caspase; 3; p53;
D O I
10.1016/j.bcp.2004.06.033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The influence of p53 function and caspase 3 activity on the capacity of the antifolate, methotrexate, to promote senescence arrest and apoptotic cell death was investigated in breast tumor cells. In p53 wild-type, but caspase 3 deficient MCF-7 breast tumor cells, death of approximately 40% of the cell population was observed immediately after acute exposure to 10 muM methotrexate (the IC80 value for a 2 h drug exposure). There was no evidence of either DNA fragmentation, a sub Go population or morphological alterations indicative of apoptosis; however, PAR-P cleavage was detected. Cell death was succeeded by growth arrest for at least 72 h-where arrest was characterized by expression of the senescence marker, beta-galactosidase. The response to methotrexate in MCF-7/E6 cells with attenuated p53 function was also primarily growth arrest-but lacking characteristics of senescence. In contrast, MCF-7 cells which expressed caspase 3 demonstrated a gradual and continuous loss of cell viability and unequivocal morphological evidence of apoptosis. DNA fragmentation indicative of apoptosis was also detected after exposure to methotrexate in p53 mutant MDA-MB231 breast tumor cells which also express caspase 3. Methotrexate-induced both p53 and p21(waf1/cip1) in MCF-7 cells within 6 h; however, no significant DNA strand breakage was evident before 18 h, suggesting that the induction of p53 reflects a response to cellular stress other than DNA damage, such as nucleotide depletion. Overall, these studies suggest that the nature of the cellular response to methotrexate depends, in large part, on p53 and caspase function. p53 appears to be required for methotrexate-induced senescence, but not apoptosis, caspase 3 is required for DNA fragmentation and the morphological changes associated with apoptosis, while neither p53 nor caspase 3 are required for methotrexate-induced growth arrest. Furthermore, the senescence phenotype may occur in the absence of direct DNA damage. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1699 / 1708
页数:10
相关论文
共 66 条
[1]   INHIBITION OF PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE TRANSFORMYLASE BY METHOTREXATE AND DIHYDROFOLIC ACID POLYGLUTAMATES [J].
ALLEGRA, CJ ;
DRAKE, JC ;
JOLIVET, J ;
CHABNER, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (15) :4881-4885
[2]  
ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720
[3]  
ALT FW, 1978, J BIOL CHEM, V253, P1357
[4]   ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA [J].
BARRY, MA ;
BEHNKE, CA ;
EASTMAN, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2353-2362
[5]   Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs [J].
Calatayud, S ;
Warner, TD ;
Mitchell, JA .
BRITISH JOURNAL OF CANCER, 2002, 86 (08) :1316-1321
[6]  
Chang BD, 1999, CANCER RES, V59, P3761
[7]   Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs [J].
Chang, BD ;
Xuan, YZ ;
Broude, EV ;
Zhu, HM ;
Schott, B ;
Fang, J ;
Roninson, IB .
ONCOGENE, 1999, 18 (34) :4808-4818
[8]   Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells [J].
Charboneau, AL ;
Singh, V ;
Yu, TX ;
Newsham, IF .
INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (02) :181-188
[9]   The vitamin D3 analog, ILX-23-7553, enhances the response to Adriamycin and irradiation in MCF-7 breast tumor cells [J].
Chaudhry, M ;
Sundaram, S ;
Gennings, C ;
Carter, H ;
Gewirtz, DA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (05) :429-436
[10]   Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells [J].
Chen, VJ ;
Bewley, JR ;
Andis, SL ;
Schultz, RM ;
Iversen, PW ;
Shih, C ;
Mendelsohn, LG ;
Seitz, DE ;
Tonkinson, JL .
BRITISH JOURNAL OF CANCER, 1998, 78 (Suppl 3) :27-34